XML 77 R55.htm IDEA: XBRL DOCUMENT
v3.20.4

Commitments and Contingencies - Other Agreements (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Jan. 31, 2018 | Aug. 31, 2017 | Dec. 31, 2016 | Oct. 31, 2014 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Mar. 31, 2017 | Dec. 16, 2016
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  | $ 157,996 | $ 96,898 | $ 90,654 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | License Patent Rights |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront fee |  |  |  | $ 200 |  |  |  |  |  |
Stock issued to licensors |  |  |  | 561,531 |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 License Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development |  |  | $ 16,500 |  |  |  |  |  |  |
Common stock issued for settlement | 150,606 | 271,347 |  |  |  |  |  | 479,270 |  |
Market capitalization |  |  |  |  | $ 2,500,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Royalties credit paid to third party (as a percent) |  |  |  |  | 50.00% |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 License Agreement | Accrued expense |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Success payment accrued |  |  |  |  | $ 15,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Success Payments | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Success payments |  |  |  |  | 10,000,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Success Payments | Minimum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Success payments |  |  |  |  | 750,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Market Cap Success Payments |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Market capitalization |  |  |  |  |  |  |  | $ 1,000,000 | $ 750,000 |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Market Cap Success Payments | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Success payments |  |  |  |  | 125,000 |  |  |  |  |
Market capitalization threshold |  |  |  |  | 10,000,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cas9-II License Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Common stock issued for settlement | 75,303 |  |  |  |  |  |  |  |  |
Market capitalization |  |  |  |  |  |  |  | $ 1,000,000 |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cas9-II License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Success payments |  |  |  |  | 30,000 |  |  |  |  |
Market capitalization threshold |  |  |  |  | 9,000,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cas9-II License Agreement | Minimum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Market capitalization threshold |  |  |  |  | 1,000,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Rare disease | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  |  |  | $ 36,000 |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Rare disease | Cpf1 License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  |  |  |  | 36,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | License Patent Rights | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  | 14,800 |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Human disease | Cpf1 License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  |  | 20,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Human disease | Cas9-II License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  |  |  |  |  |  |  | $ 3,700
Potential liability for future sales milestone payments |  |  |  |  | 13,500 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Rare disease | Cpf1 License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  |  | 6,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Rare disease | Cas9-II License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  |  | 1,100 |  |  |  |  |
Potential liability for future sales milestone payments |  |  |  |  | 9,000 |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States and one other | Human disease | License Patent Rights | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  | 4,100 |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | UNITED STATES | Human disease | License Patent Rights | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  |  |  | $ 54,000 |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | UNITED STATES | Human disease | Cpf1 License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  |  |  |  | $ 54,000 |  |  |  |  |

X
- Definition The potential liability for company's sale success payments. + References No definition available. + Details
Name: | edit_CompanySaleSuccessPaymentsUnderPatentRights
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of common shares issued for settlement under the license agreement. + References No definition available. + Details
Name: | edit_LicenseAgreementNumberOfCommonStockIssuedForSettlement
Namespace Prefix: | edit_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of market capitalization. + References No definition available. + Details
Name: | edit_MarketCapitalization
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the market capitalization threshold under license agreement. + References No definition available. + Details
Name: | edit_MarketCapitalizationThreshold
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents upfront payment fees to collaborators under agreements. + References No definition available. + Details
Name: | edit_PaymentsForUpfrontFeesToCollaborators
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of third party royalties that may be credited against the royalties due to counter party. + References No definition available. + Details
Name: | edit_PercentageOfRoyaltiesPaidCreditedTowardsRoyaltiesDue
Namespace Prefix: | edit_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate potential liability for future clinical and regulatory milestone payments related to product approval. + References No definition available. + Details
Name: | edit_PotentialLiabilityForProductApprovalClinicalAndRegulatoryMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The potential liability for sales milestone payments. + References No definition available. + Details
Name: | edit_PotentialLiabilityForSalesMilestones
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of success payment accrued. + References No definition available. + Details
Name: | edit_SuccessPaymentAccrued
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=edit_HarvardBroadMitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_LicensePatentRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_Cpf1LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_Cpf1SuccessPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_Cpf1MarketCapSuccessPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_Cas9IILicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=edit_ProductForTreatmentOfRareDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=edit_UnitedStatesEuropeAndJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=edit_ProductForTreatmentOfHumanDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=edit_UnitedStatesAndOneOtherLocationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |